Stock Track | BAO PHARMA-B Soars 5.80% in Intraday Trading on MSCI Inclusion, Share Buyback and Drug Pipeline Progress

Stock Track05-19

BAO PHARMA-B's stock surged 5.80% during Tuesday's intraday session, driven by multiple positive catalysts that boosted investor sentiment.

The rally was primarily fueled by the company's recent inclusion in the MSCI Global Small Cap Index, with the adjustment set to take effect after the close on May 29. This inclusion is expected to attract incremental passive fund allocation, enhance market liquidity, and elevate the company's international visibility among global institutional investors.

Additional supportive factors include controlling shareholder Dr. Liu Yanjun's ongoing plan to acquire up to 38.8939 million H shares within three months, and the company's injectable KJ103 — a first-in-class recombinant IgG-degrading enzyme for desensitization therapy in highly sensitized kidney transplant patients — being proposed for priority review by the CDE. These developments have reinforced market confidence in the company's pipeline and long-term growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193885963?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 10:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193885963","market":"hk","top_or_hot":-1,"title":"Stock Track | BAO PHARMA-B Soars 5.80% in Intraday Trading on MSCI Inclusion, Share Buyback and Drug Pipeline Progress","media":"Stock Track","content":"<p>BAO PHARMA-B's stock surged 5.80% during Tuesday's intraday session, driven by multiple positive catalysts that boosted investor sentiment.</p><p>The rally was primarily fueled by the company's recent inclusion in the MSCI Global Small Cap Index, with the adjustment set to take effect after the close on May 29. This inclusion is expected to attract incremental passive fund allocation, enhance market liquidity, and elevate the company's international visibility among global institutional investors.</p><p>Additional supportive factors include controlling shareholder Dr. Liu Yanjun's ongoing plan to acquire up to 38.8939 million H shares within three months, and the company's injectable KJ103 — a first-in-class recombinant IgG-degrading enzyme for desensitization therapy in highly sensitized kidney transplant patients — being proposed for priority review by the CDE. These developments have reinforced market confidence in the company's pipeline and long-term growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BAO PHARMA-B Soars 5.80% in Intraday Trading on MSCI Inclusion, Share Buyback and Drug Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BAO PHARMA-B Soars 5.80% in Intraday Trading on MSCI Inclusion, Share Buyback and Drug Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-19 10:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAO PHARMA-B's stock surged 5.80% during Tuesday's intraday session, driven by multiple positive catalysts that boosted investor sentiment.</p><p>The rally was primarily fueled by the company's recent inclusion in the MSCI Global Small Cap Index, with the adjustment set to take effect after the close on May 29. This inclusion is expected to attract incremental passive fund allocation, enhance market liquidity, and elevate the company's international visibility among global institutional investors.</p><p>Additional supportive factors include controlling shareholder Dr. Liu Yanjun's ongoing plan to acquire up to 38.8939 million H shares within three months, and the company's injectable KJ103 — a first-in-class recombinant IgG-degrading enzyme for desensitization therapy in highly sensitized kidney transplant patients — being proposed for priority review by the CDE. These developments have reinforced market confidence in the company's pipeline and long-term growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1193885963","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193885963","pubTimestamp":1779157646,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BAO PHARMA-B's stock surged 5.80% during Tuesday's intraday session, driven by multiple positive catalysts that boosted investor sentiment.The rally was primarily fueled by the company's recent...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"个股轨迹|宝药业-B盘中大涨5.80%受MSCI纳入、股份回购及药物管线进展影响","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"BAO PHARMA-B's stock surged 5.80% during Tuesday's intraday session, driven by multiple positive catalysts that boosted investor sentiment.The rally was primarily fueled by the company's recent inclusion in the MSCI Global Small Cap Index, with the adjustment set to take effect after the close on May 29. This inclusion is expected to attract incremental passive fund allocation, enhance market liquidity, and elevate the company's international visibility among global institutional investors.Additional supportive factors include controlling shareholder Dr. Liu Yanjun's ongoing plan to acquire up to 38.8939 million H shares within three months, and the company's injectable KJ103 — a first-in-class recombinant IgG-degrading enzyme for desensitization therapy in highly sensitized kidney transplant patients — being proposed for priority review by the CDE. These developments have reinforced market confidence in the company's pipeline and long-term growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193885963","isCrawlerRequest":true}